DHR

Danaher Corp.'s stock has experienced several notable events over the past six months: on October 7, 2026, Danaher announced plans for its first AI-powered autonomous lab for antibody research, leading to a 2% premarket gain, and Barclays raised its price target to $255. On October 1, 2026, Guggenheim increased its price target to $250. On September 29, 2026, the stock pulled back despite positive developments like Leica Biosystems acquiring StatLab Medical Products and Goldman Sachs raising its price target to $250. Goldman Sachs had also raised its price target to $250 on September 24, 2026. The stock reached a 4-week high on September 22, 2026, and a 5-week low on September 11, 2026. On August 19, 2026, the stock hit a 24-week high. On August 14, 2026, Danaher reported Q2 2026 results with revenue up 5.5% year-over-year and adjusted EPS increasing by 8%, projecting 3-4% core growth for the full fiscal year. On June 10, 2026, the company completed the acquisition of Masimo for approximately $9.8 billion. Overall, the stock climbed approximately 19% over the 90 days leading up to September 29, 2026.